I finally got around to reading all 14 of EXEL's . The ones dealing with Cabozantinib in lung cancer are the most interesting. In particular abstract # 8003. In Cabo vs. erlotinb- Cabo was much better p=0.0002 and erlotinib + Cabo was better then E or C alone p=0.0002 What does this mean ? Cabo will get approved for NSCLC patients who have certain types of DNA mutations that respond to Cabo.
Biogen is doing great and Scangos helped develop all EXEL's current products. Do you think Biogen might make a buyout offer for EXEL ?
Today's Wall St. Journal had an article about the price of natural gas going up due to electric generators switching out of coal. So why is the stock price dropping ?
Where are the shorts going to find 50 million shares (as of April15) in order to make an exit ?
The ASCO results look very positive so who will sell except at a very high price
Short squeeze anyone ?
If EXEL was part of a big pharma company they would have quickly started a couple of new trials by now. One with your group of patients visceral mets and one with patients who have failed all the other newer drugs such as Xifigo. Usually trials are conducted with patients who have failed all available drugs so the patients have no salvage therapy option to move on to. The bottom line is that Cabo works in prostate cancer but more trials are needed to prove it.
Did you read abstract #139 at the ASCO GU ? PFS was 0.001 but then 60% of the patients left to take salvage therapy. That alone ruins any OS data.
but PGNX paid for it by a big drop in stock price. The Salix inventory stuffing gig was crazy but the stockholders made out in the buyout.
SSE and CHK have some long term leases. However, when they end in 4 mo. to 1 yr. things look pretty bleak.
DNDN completely over estimated the sales potential of Provenge and proceeded to build 3 very large manufacturing plants for half a billion $. If they estimated sales correctly then they would still be around.